« Return to News | R&D Trends | Drug Sponsors

Biogen Idec announces 2012 goals

Wednesday, January 11, 2012 11:15 AM

Growing its leadership position in multiple sclerosis (MS), advancing its late-state pipeline, leveraging R&D capabilities to grow its early-stage pipeline and preparing for potential launches of new high-impact therapies are among Biogen Idec’s recently announced 2012 strategic priorities.

To grow its leadership position in MS, Biogen Idec plans to advance its Avonex franchise, expand Fampyra’s European footprint through additional launches and boost Tysabri sales by better identifying patients at risk of side effects.

Advancing Biogen Idec’s late-stage pipeline will be achieved by continuing to advance the daclizumb phase III program in MS, as well as delivering the data readout from the first phase III trial of dexpramipexole in ALS by year-end.

Biogen Idec said it hopes to grow its early-state pipeline by building world-class scientific teams in core therapeutic areas; advancing the company’s internal early-state pipeline programs; advancing existing collaborations (e.g., Porola Pharmaceuticals, Isis Pharmaceuticals); entering into new collaborations in neurology, immunology and hemophelia; continuing to focus its research and early discovery efforts and increasing its emphasis on translational research (e.g., biomarker and imaging technologies).

Through its joint venture with Samsung, Biogen Idec said it hopes to leverage its expertise and capabilities in protein engineering, cell line development and recombinant biologics manufacturing to position the company to participate in the emerging market for biosimilars.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.